DigestRedComo funciona
Red
/
Empresas
Su
No verificado

Summit Therapeutics Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

39 Comunicados de prensa

Ver todos los comunicados de prensa
30/06/2025
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Mercado laboral
Industria
Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
Fuente
Summit Therapeutics Inc.
Editor
Business Wire
1.00
0
06/06/2025
Mercado de valores
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Medicina - Varios
Sanidad
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fuente
Summit Therapeutics Inc.
Editor
Business Wire
1.00
0
05/06/2025
Eventos
Web y redes sociales
Biotecnología
Farmacéutica
Salud
Oncología
Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
Fuente
Summit Therapeutics Inc.
Editor
Business Wire
1.00
0
30/05/2025
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Industria
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study
Fuente
Summit Therapeutics Inc.
Editor
Business Wire
1.00
0
16/05/2025
Mercado de valores
Finanzas
Ciencia
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Sanidad
Oncología
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fuente
Summit Therapeutics Inc.
Editor
Business Wire
1.00
0
01/05/2025
Web y redes sociales
Telefonía
Mercado de valores
Biotecnología
Farmacéutica
Salud
Oncología
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025
Fuente
Summit Therapeutics Inc.
Editor
Business Wire
1.00
0
25/04/2025
Industria
Ciencia
Biotecnología
Farmacéutica
Oncología
Sanidad
Salud
Medicina - Varios
Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China
Fuente
Summit Therapeutics Inc.
Editor
Business Wire
1.00
0
24/04/2025
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Biotecnología
Farmacéutica
Salud
Oncología
Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025
Fuente
Summit Therapeutics Inc.
Editor
Business Wire
1.00
0
23/04/2025
Industria
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Medicina - Varios
Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China
Fuente
Summit Therapeutics Inc.
Editor
Business Wire
1.00
0
04/04/2025
Mercado de valores
Finanzas
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Medicina - Varios
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fuente
Summit Therapeutics Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0